<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04279769</url>
  </required_header>
  <id_info>
    <org_study_id>CX-280-202</org_study_id>
    <nct_id>NCT04279769</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis</brief_title>
  <official_title>A Phase 1b Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b multiple ascending dose escalation study to evaluate the safety and
      tolerability of arginase inhibitor CB-280 in subjects with cystic fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study CX-280-202 is a Phase 1b, randomized, double-blind, placebo-controlled, multiple
      ascending dose escalation study of CB-280 in adult subjects with cystic fibrosis and chronic
      infection with Pseudomonas aeruginosa. The study will evaluate the safety, pharmacokinetics,
      pharmacodynamics, and biological activity of CB-280 in approximately 32 adult patients with
      cystic fibrosis. There are four planned sequential dose escalation cohorts of 8 subjects
      each, randomized 6:2 to receive CB-280 or matched placebo at doses of 50 mg, 100 mg, 200 mg,
      or 400 mg administered twice daily for 14 days. Intermediate dose levels may be evaluated
      based on emerging safety data at the planned dose levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety and tolerability of CB-280 in adult cystic fibrosis patients: incidence and severity of adverse event (AEs) assessed by Common Terminology Criteria for Adverse Events, version 5 (CTCAE v5.0)</measure>
    <time_frame>Start of treatment to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of plasma CB-280 measured by Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of plasma CB-280 measured by area under the plasma concentration versus time curve, from time 0 to the last observed non-zero concentration (AUC 0-t)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-280 twice daily at 50 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-280 twice daily at 100 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-280 twice daily at 200 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-280 twice daily at 400 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-280</intervention_name>
    <description>CB-280, oral capsule administered twice daily at the assigned dose level for 14 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo oral capsule administrated twice daily at the assigned dose level for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria: Inclusion Criteria:

          1. Written Informed Consent in accordance with federal, local, and institutional
             guidelines

          2. Confirmed diagnosis of cystic fibrosis

          3. Male or female subjects â‰¥ 18 years on the date of informed consent

          4. Percent predicted FEV1 of 40-90% at screening per Global Lung Function Initiative
             (GLI) equation

          5. Clinically stable with no significant changes in health status within 28 days prior to
             Day 1

          6. Chronic lung infection with P. aeruginosa defined as at least two (2) positive sputum
             cultures in the past year, one of which was collected within the 6 months preceding
             Day 1

          7. Stable cystic fibrosis medication regimen for at least 28 days inclusive of CFTR
             modulators prior to Day 1

          8. Hemoglobin &gt; 10 g/dL at screening

          9. Glomerular filtration rate &gt; 50 mL/min/1.73 m2 at screening

         10. Normal liver function at screening

        Exclusion Criteria:

          1. History of any comorbidity that, in the opinion of the Investigator, might pose an
             additional risk in administering study drug to the subject or confound the results of
             the study

          2. Colonization with Burkholderia species or non-tuberculous Mycobacterium species,
             defined as at least one positive sputum culture in the preceding 6 months

          3. Unable to receive study medication per os (PO)

          4. Females who are pregnant, have a positive pregnancy test at screening, or are nursing
             (lactating)

        Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emil T Kuriakose, MD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Bioscience</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Administrator</last_name>
    <phone>650-870-1000</phone>
    <email>clinicaltrials@calithera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cystic Fibrosis Institute</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Cruz</last_name>
      <phone>847-998-3434</phone>
    </contact>
    <investigator>
      <last_name>Steven Boas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan White</last_name>
      <phone>913-917-8292</phone>
    </contact>
    <investigator>
      <last_name>Joel Mermis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Medical College at Westchester Medical Center</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Ramirez</last_name>
      <phone>914-593-8904</phone>
    </contact>
    <investigator>
      <last_name>Allen Dozor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hershey Medical Center Pennsylvania State University</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Diane Kitch</last_name>
      <phone>717-531-5646</phone>
    </contact>
    <investigator>
      <last_name>Judie Howrylak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arginase inhibitor</keyword>
  <keyword>CB-280</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

